Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

A potential role for psilocybin in the treatment of obsessive-compulsive disorder

Edward Jacobs

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (135)

  1. Emotions and brain function are altered up to one month after a single high dose of psilocybin. 2020-02-10 · Expand citations
  2. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. 2020-02-01 · Expand citations
  3. REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. 2019-07-01 · Expand citations
  4. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels 2019-06-01 · Expand citations
  5. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. 2018-07-01 · Expand citations
  6. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. 2018-02-01 · Expand citations
  7. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. 2017-10-13 · Expand citations
  8. Long-term follow-up of psilocybin-facilitated smoking cessation. 2017-01-01 · Expand citations
  9. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. 2017-01-01 · Expand citations
  10. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. 2016-12-01 · Expand citations
  11. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. 2016-12-01 · Expand citations
  12. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. 2016-12-01 · Expand citations
  13. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. 2016-01-01 · Expand citations
  14. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. 2015-11-01 · Expand citations
  15. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. 2015-10-15 · Expand citations
  16. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. 2015-03-01 · Expand citations
  17. Psychedelics not linked to mental health problems or suicidal behavior: a population study. 2015-03-01 · Expand citations
  18. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. 2015-01-01 · Expand citations
  19. Psilocybin and Obsessive Compulsive Disorder. 2014-01-01 · Expand citations
  20. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. 2014-01-01 · Expand citations
  21. Broadband cortical desynchronization underlies the human psychedelic state. 2013-09-18 · Expand citations
  22. Psychedelics and mental health: a population study. 2013-01-01 · Expand citations
  23. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. 2012-12-01 · Expand citations
  24. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. 2012-02-07 · Expand citations
  25. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. 2012-02-01 · Expand citations
  26. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. 2011-12-01 · Expand citations
  27. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. 2011-11-01 · Expand citations
  28. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. 2011-11-01 · Expand citations
  29. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. 2011-01-01 · Expand citations
  30. Effects of Psilocybe argentipes on marble-burying behavior in mice. 2009-08-01 · Expand citations
  31. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. 2008-01-01 · Expand citations
  32. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. 2006-11-01 · Expand citations
  33. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. 2004-03-01 · Expand citations
  34. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. 1998-12-01 · Expand citations
  35. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man 1997-06-01 · Expand citations
  36. Serotonin, psilocybin, and body dysmorphic disorder: a case report. 1996-04-01 · Expand citations
  37. Relief of obsessive-compulsive symptoms by LSD and psilocin 1987-09-01 · Expand citations
  38. Some biochemical studies on psilocybin and psilogin. 1963-04-01 · Expand citations
  39. [Elucidation of the structure and the synthesis of psilocybin]. 1958-11-15 · Expand citations
  40. OpenAlex W122113993
  41. OpenAlex W1784226620
  42. OpenAlex W1846321575
  43. OpenAlex W1964540177
  44. OpenAlex W1964698313
  45. OpenAlex W1965761294
  46. OpenAlex W1971459727
  47. OpenAlex W1978032191
  48. OpenAlex W1985748616
  49. OpenAlex W1995045083
  50. OpenAlex W1997161439
  51. OpenAlex W1997392319
  52. OpenAlex W1997452831
  53. OpenAlex W2001090794
  54. OpenAlex W2002443895
  55. OpenAlex W2005593798
  56. OpenAlex W2006587749
  57. OpenAlex W2012077435
  58. OpenAlex W2015011531
  59. OpenAlex W2029342476
  60. OpenAlex W2034593916
  61. OpenAlex W2036037381
  62. OpenAlex W2038928427
  63. OpenAlex W2042298460
  64. OpenAlex W2042307631
  65. OpenAlex W2043711264
  66. OpenAlex W2054754029
  67. OpenAlex W2055110970
  68. OpenAlex W2058064963
  69. OpenAlex W2063955964
  70. OpenAlex W2068751924
  71. OpenAlex W2071765462
  72. OpenAlex W2072467374
  73. OpenAlex W2076256173
  74. OpenAlex W2078740239
  75. OpenAlex W2080123927
  76. OpenAlex W2082535915
  77. OpenAlex W2089130066
  78. OpenAlex W2095643440
  79. OpenAlex W2098915263
  80. OpenAlex W2100861230
  81. OpenAlex W2101309614
  82. OpenAlex W2101582587
  83. OpenAlex W2104320372
  84. OpenAlex W2108292201
  85. OpenAlex W2111396411
  86. OpenAlex W2113099805
  87. OpenAlex W2120128279
  88. OpenAlex W2120918936
  89. OpenAlex W2129502536
  90. OpenAlex W2136435696
  91. OpenAlex W2140018908
  92. OpenAlex W2140172277
  93. OpenAlex W2159370497
  94. OpenAlex W2159990726
  95. OpenAlex W2166952073
  96. OpenAlex W2167273704
  97. OpenAlex W2171432760
  98. OpenAlex W2204342160
  99. OpenAlex W2319006982
  100. OpenAlex W2336389811
  101. OpenAlex W2341558148
  102. OpenAlex W2345258591
  103. OpenAlex W2551626080
  104. OpenAlex W2552814605
  105. OpenAlex W2593476122
  106. OpenAlex W2596797494
  107. OpenAlex W2609660019
  108. OpenAlex W2774876719
  109. OpenAlex W2780408016
  110. OpenAlex W2786472900
  111. OpenAlex W2788854095
  112. OpenAlex W2791704659
  113. OpenAlex W2792211781
  114. OpenAlex W2801279915
  115. OpenAlex W2804362986
  116. OpenAlex W2808301300
  117. OpenAlex W2889525702
  118. OpenAlex W2894846833
  119. OpenAlex W2895529315
  120. OpenAlex W2898717395
  121. OpenAlex W2987203272
  122. OpenAlex W2999812626
  123. OpenAlex W3108285700
  124. OpenAlex W3142791708
  125. OpenAlex W3217097423
  126. OpenAlex W4211150788
  127. OpenAlex W4211211437
  128. OpenAlex W4386315766
  129. OpenAlex W592732404
  130. OpenAlex W62922542
  131. OpenAlex W6649587555
  132. OpenAlex W6748386387
  133. OpenAlex W6755698176
  134. OpenAlex W6819150864
  135. OpenAlex W6821717516

Cited by — these papers cite this paper (2)

  1. Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins 2026-04-21 · Expand citations
  2. PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin 2024-07-24 · Expand citations